#Israel #Tel Aviv #Everads #Retina #Suprachoroidal

Everads Therapy Unveils Groundbreaking Findings at ASRS 2025

Everads Therapy, a pioneering clinical-stage biotechnology company, is making significant strides in the field of retinal treatments with its cutting-edge suprachoroidal delivery technology. At the upcoming 2025 American Society of Retina Specialists (ASRS) Annual Meeting, the company will showcase two critical oral presentations that will include comprehensive results from its initial human clinical trials, as well as novel preclinical outcomes demonstrating the utility of its suprachoroidal injector in a minimally invasive setting.

Promising Clinical Results

The highlight of Everads' presentation will undoubtedly be the full results from its first-in-human trial of the Everads Injector, which evaluates its safety, performance, and tolerability in administering a triamcinolone acetonide suspension to patients suffering from diabetic macular edema.

According to Moshe Weinstein, Executive Chairman of Everads Therapy, "We are thrilled to present the comprehensive dataset from our clinical study, which underlines not only the safety and effectiveness of our suprachoroidal injector but also its potential application in treating retinal detachment in an office-based environment."

The clinical study (NCT06314217) affirmed that the injector is user-friendly and feasible for outpatient use, providing a significant advancement toward more accessible retinal treatments.

Innovations in Retinal Detachment Repair

In addition to patient trials, Everads will share groundbreaking preclinical data that further cements its injector's role in addressing retinal detachment. A study conducted on human cadaver eyes showed that the injector could accurately deliver viscoelastic materials into the suprachoroidal space, successfully producing predictable buckles. Dr. Gareth D. Mercer, MD, PhD, who contributed to this research, noted the importance of this technology as an alternative to traditional, more invasive surgical methods. "The study illustrates not just the feasibility of using the Everads Injector but also its capability to enhance the recovery experience for patients facing retinal detachment," said Mercer.

Expanding Treatment Horizons

Recognizing the complexities involved in repairing retinal detachments, especially when considering patient comfort and recovery time, Everads is positioned to lead the way in developing less invasive treatments. The company's strategic approach seeks to address the growing demand for cost-effective, patient-centered solutions targeting retinal diseases. The data presented at ASRS 2025 will include insights into the relationship between injection volume and buckle size, further validating the injector's effectiveness as a non-surgical alternative.

Presentation Details at ASRS 2025

The two key presentations at the ASRS 2025 will feature:

• - Minimally Invasive Suprachoroidal Buckling Using a Novel Injector: Preclinical Evaluation in Human Cadaver Eyes, presented by Dr. Mercer on July 31st at 8:28 AM in Hall B.
• - First-in-Human Study Using a Novel Suprachoroidal Injector, led by Dr. Yoreh Barak, scheduled for August 2nd at 4:27 PM in Hall B.

About Everads Therapy

Everads Therapy is on a mission to revolutionize retinal disease treatment through its proprietary suprachoroidal delivery platform, uniquely designed for rapid and safe drug distribution via non-surgical, in-office injections. Their innovation doesn’t stop at just treating retinal diseases; the company is also committed to collaborating with partners across various treatment modalities, including gene therapy and cell therapy, to enhance their suprachoroidal platform's potential. Originating as a spin-out from DALI Medical Devices, Everads is proud to be under the guidance of RAD Biomed — a leading biotech accelerator — and uses cutting-edge technologies licensed from the esteemed Prof. Y Rotenstreich at Sheba Tel Hashomer Medical Center.

For further updates and information regarding their research, visit www.everads-therapy.com and follow Everads Therapy on LinkedIn for the latest news.